Skip to Content
  • AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking abo… Read More
  • Sodium Benzoate Nonsense

    I don’t spend a lot of time on the blog swatting down idiotic ideas about chemicals. It’s a full time job, and (see next post) I already have a full… Read More
  • Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you… Read More
  • A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I… Read More
  • Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground… Read More
  • Revusiran’s Failure Revisited

    I wrote about Alnylam’s recent clinical disaster here, where they had to stop a Phase III siRNA therapy trial against a rare amyloidosis with cardiac com… Read More
  • Alnylam Blindsided

    Alnylam, the big name in RNAi therapeutics, had an awful day of it yesterday, and is having another one today. More may be on the way. Rivusiran, their Phase II… Read More
Page 1 of 1812345...10...Last »